BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 118 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q3 2019. The put-call ratio across all filers is 0.13 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2021 | $611,000 | +44.8% | 60,000 | +6.0% | 0.02% | +57.1% |
Q4 2020 | $422,000 | +62.3% | 56,600 | -25.1% | 0.01% | +55.6% |
Q3 2020 | $260,000 | -31.9% | 75,600 | -5.7% | 0.01% | -10.0% |
Q2 2020 | $382,000 | +126.0% | 80,200 | -5.3% | 0.01% | +100.0% |
Q1 2020 | $169,000 | -70.5% | 84,700 | -43.9% | 0.01% | -61.5% |
Q2 2019 | $572,000 | -70.1% | 150,998 | -35.7% | 0.01% | -66.7% |
Q1 2019 | $1,913,000 | +2.5% | 234,898 | +1.6% | 0.04% | -2.5% |
Q4 2018 | $1,866,000 | +1.0% | 231,198 | -4.5% | 0.04% | +21.2% |
Q3 2018 | $1,847,000 | +29.8% | 241,998 | -2.5% | 0.03% | +32.0% |
Q2 2018 | $1,423,000 | +1.0% | 248,198 | -15.9% | 0.02% | +4.2% |
Q1 2018 | $1,409,000 | +3.4% | 295,166 | +6.3% | 0.02% | +4.3% |
Q4 2017 | $1,363,000 | +247.7% | 277,567 | +271.6% | 0.02% | +155.6% |
Q3 2017 | $392,000 | +166.7% | 74,700 | +398.0% | 0.01% | +80.0% |
Q3 2014 | $147,000 | +104.2% | 15,000 | +51.5% | 0.01% | +66.7% |
Q3 2013 | $72,000 | – | 9,900 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
VHCP Management, LLC | 1,744,356 | $18,455,000 | 9.59% |
RA Capital Management | 4,347,456 | $45,996,000 | 3.30% |
Cormorant Asset Management, LP | 1,168,000 | $12,357,000 | 2.84% |
Baker Brothers Advisors | 5,867,031 | $62,073,000 | 0.79% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 907,920 | $9,606,000 | 0.39% |
QVT Financial LP | 525,734 | $5,562,000 | 0.32% |
EAM Investors, LLC | 114,548 | $1,212,000 | 0.22% |
FRANKLIN STREET ADVISORS INC /NC | 93,000 | $984,000 | 0.20% |
THB ASSET MANAGEMENT | 301,529 | $3,190,000 | 0.19% |
TPG Group Holdings (SBS) Advisors, Inc. | 1,162,269 | $12,297,000 | 0.13% |